Clinical Research Directory

Inclusion Criteria: 1. Patients with clinical stage IIA-IIIA lung adenocarcinoma after radical surgery (patients within 6 weeks after surgery); 2. Negative driver gene expression (no EGFR, ALK, ROS1 mutations) and PD-1/L1 expression \<1%; 3. Meets the diagnostic criteria for Qi-Yin Deficiency Syndrome. The primary symptoms include cough, low sputum, shortness of breath, hoarseness, weakness, and thirst without wanting to drink. Secondary symptoms include spontaneous, night sweat, dysphoria in chestpalms-soles, red tongue or tooth-marked tongue, and a weak pulse. At least two primary symptoms and one of the secondary symptoms are present; 4. Patients aged between 18-75 years; 5. Patients with basically normal blood and biochemical indices, etc., without serious viral or bacterial infections; patients without organ failure and serious heart disease (blood bilirubin \<68 μmol/L, aspartate aminotransferase \<90 IU/L, creatinine \<350 μmol/L, white blood cell count \>3.5 × 109/L and less than 12 × 109/L, platelet count \>80 × 109/L, and (erythrocyte pressure area \>0.20); 6. Tumour PS score ≤2 and no other serious comorbidities; 7. The subjects themselves were well informed and agreed to participate in the study by signing an informed consent form and had good compliance; 8. Non-pregnant and lactating patients; 9. Passing the chemotherapy-related indexes; 10. No allergic reaction to the ingredients in the formula. Exclusion Criteria: 1. Patients who are incompletely resected or whose cancer has undergone recurrence or metastasis; 2. Patients who are being treated with other drugs or therapies (including other Chinese herbal medicines, immunological drugs, radiotherapy, etc.); 3. Patients who are themselves mentally ill and have a lack of autonomous behaviour; 4. Women who are pregnant, preparing for pregnancy or breastfeeding; 5. Combined heart, lung, brain, liver, kidney and haematopoietic system and other serious diseases, psychiatric patients; 6. Allergic or known hypersensitivity to the components of the drug; 7. Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months; 8. Alcohol and/or psychoactive substances abuse, drug abusers and dependent persons; 9. Other pathologies or conditions that, in the judgement of the investigator, have the effect of reducing the likelihood of enrolment or complicating enrolment, e.g., frequent changes in the work environment, unstable living conditions, and other conditions that predispose to loss of visits.